Encouraging Outcomes Data with Surgical Repair of Chronic, Large, Refractory Macular Holes Using AmnioGraft® Cryopreserved Amniotic Membrane

Encouraging Outcomes Data with Surgical Repair of Chronic, Large, Refractory Macular Holes Using AmnioGraft® Cryopreserved Amniotic Membrane Preliminary case series show that AmnioGraft use in the repair of persistent or recurrent Macular Hole defects can lead to improved visual recovery and retinal morphology Miami, FL – September 14, 2020 — Bio-Tissue, Inc., a TissueTech, Inc. […]

Bio-Tissue Announces First Annual National Mechanical Dry Eye Day

Bio-Tissue Announces First Annual National Mechanical Dry Eye Day Day to bring awareness to Mechanical Dry Eye (MDE), one of the most overlooked and often misdiagnosed age-related eye conditions Miami, FL – April 10, 2020 – Bio-Tissue, Inc., a TissueTech, Inc. company and leader in the clinical application of cryopreserved amniotic membrane products for ocular […]

Leading Experts in Ophthalmology Come Together to Establish New Standard of Care Consensus Guidelines for Using Cryopreserved Amniotic Membrane to Treat Corneal Diseases

Leading Experts in Ophthalmology Come Together to Establish New Standard of Care Consensus Guidelines for Using Cryopreserved Amniotic Membrane to Treat Corneal Diseases Published reference guide shares acquired knowledge about utilizing cryopreserved amniotic membrane (CAM) at earlier stages of treatment for cornea-involved ocular surface diseases Miami, FL – April, 10,2020 — Bio-Tissue, Inc. (Bio-Tissue), a […]

Clinical Results of Using Amniotic Membrane-Umbilical Cord Graft for Reducing Glaucoma Shunt Tube Exposure Published in Ophthalmology Glaucoma Journal

Miami, FL – December 10, 2019 – Bio-Tissue, Inc., a TissueTech, Inc. company and leader in the clinical application of amniotic membrane and umbilical cord birth tissue products for unmet patient needs, announced today that the results from a clinical study on the use of amniotic membrane – umbilical cord grafts have been published in Ophthalmology Glaucoma, the peer-reviewed publication for the American Academy of Ophthalmology® in partnership with the American Glaucoma Society.

Bio-Tissue Launches Website to Educate on Long-Lasting Solution for Mechanical Dry Eye (MDE), aka Conjunctivochalasis (CCh)

Miami, FL – November 12, 2019 – Bio-Tissue, Inc., a TissueTech, Inc. company and leader in the clinical application of amniotic membrane and umbilical cord-based products for unmet patient needs, announced today the launch of an educational website, www.DiscoverMDE.com , on Mechanical Dry Eye, MDE, also sometimes referred to as Conjunctivochalasis (CCh). The website features educational information, videos, testimonials and other resources for both patients and health care providers.

Bio-Tissue Founder, Pioneer in Ocular Use of Amniotic Membrane Mentors Minority Students During 2019 American Academy of Ophthalmology Meeting

Miami, FL – November 4, 2019 – Scheffer C.G. Tseng, MD, PhD, Chief Technology Officer and co-founder of Bio-Tissue, Inc., a TissueTech company, shared insights with underrepresented undergraduates and medical students about the rewards and opportunities of studying ophthalmology during their residencies at this year’s Minority Ophthalmology Mentoring Program on October 13, 2019 at the American Academy of Ophthalmology’s annual meeting in San Francisco.

TissueTech Names New Vice President to Lead Human Resources Operations and Process Improvement Initiatives

Miami, FL – October 2, 2019– TissueTech,™ Inc., a pioneer and market leader in the development and clinical application of human birth tissue products, today announced the appointment of Kim Tripodo to the role of Vice President of Human Resources. In this role, Ms. Tripodo will be responsible for all aspects of human resource functions and employee-related initiatives.

TissueTech Names New Vice President to Oversee Scale Up of Product Lifecycle Management and Technology Transfer Activities

Miami, FL – September 23, 2019– TissueTech™, Inc., a pioneer in the development and clinical application of regenerative human birth tissue products, today announced the appointment of Jerry Chang, PhD to the position of Vice President of Product Development. In this new role, Dr. Chang will have oversight for ensuring the efficiency and integrity of all Product Lifecycle Management activities and will control the processes and testing of biological products for human use as the Company moves closer to commercialization of its birth tissue products as biologics.

Bio-Tissue Expands National Footprint, Ramps Up Sales Force by More than 25 Percent

Miami, FL – September 11, 2019 – Bio-Tissue®, Inc., a TissueTech,™ Inc. company, and pioneer and market leader in the development and clinical application of Cryopreserved Amniotic Membrane (CAM) products for ocular surface disease and injury, today announced the expansion of its sales force to more effectively meet the needs of clinicians and their patients.

TissueTech Appoints New Vice President to Drive Assurance Strategy for all Product Development and Manufacturing Activities

Miami, FL – September 5, 2019 – TissueTech™, Inc., a pioneer in the development and clinical application of regenerative human birth tissue products, today announced the appointment of Sherry Saurini to the position of Vice President of Quality Assurance. In her new role, Ms. Saurini will have oversight for ensuring that the company is maintaining set requirements for the manufacture of birth tissue products for human use as the company moves closer to commercialization as a biologics provider.

TissueTech Expands its Clinical Program with Medidata’s End-to-end Unified Platform

Miami, Fla. – July 3, 2019 –  Medidata announced that TissueTech, Inc.. has chosen the Medidata Rave Clinical Cloud™ as its end-to-end platform for clinical trials. TissueTech recognizes this partnership as critical to helping spearhead the company’s transformation in biologics with a focus on regenerative therapies derived from human birth tissue for patients with serious unmet clinical needs.

TissueTech Raises $82 million in latest round of equity financing

Miami, Fla. – June 26, 2019 – TissueTech, Inc., the pioneer in regenerative medicine utilizing human umbilical cord and amniotic membrane, today announced the closing of an $82.25 million round of Preferred C equity financing led by EW Healthcare Partners (formerly Essex Woodlands) and followed by the third round of continuous investments from Ballast Point Ventures.